Mead Johnson unveils $325m Singaporean production and R&D site
The US$325m (€256m) Tuas, Singapore site, which represents Mead Johnson's single largest capital investment in its history, will manufacture ingredients and products for a number of "strategic, fast growing" markets in Asia.
The adjacent R&D center will, meanwhile, "add to the company's ability to advance pediatric nutrition science and product innovation," the company said in a statement.
Around 180 positions across production and research will be created at the Tuas site.
Commenting, James Cornelius, chairman, Mead Johnson Nutrition, branded the investment an “acknowledgement of the double-digit growth in demand for the company’s products in Asia over the past decade.”
“More importantly, the investment reflects the strong prospects for future growth and expansion in this region."
“Breakthroughs made here will help improve existing products and develop new ones to support the healthy growth and development of infants and children in Singapore, Asia and around the world," said Cornelius.
Mead Johnson Nutrition products, including Enfamil brand infant formula and Enfagrow follow-on formula, are marketed in Singapore, neighbouring Malaysia and Indonesia, and across mainland Asia.
More than half of Mead Johnson revenue comes from Asia.
In 2013, the Illinois-based company recorded total group revenue of US$4.2bn (€3.3bn). Asian sales accounted for US$2.17bn (€1.7bn) of this total.
